Daniel Petrylak, MD, on the current role of CTC tumor cell components via liquid biopsy PC treatment

Technological developments for CTC researchПодробнее

Role of Circulating Tumor Cells/DNA & Liquid Biopsy in Melanoma - David PolskyПодробнее

Repeat Molecular Testing in Advanced Prostate CancerПодробнее

Daniel Petrylak, MD, shares potential efficacy when adding immunotherapy such as sip-T in mCRPCПодробнее

Daniel Petrylak, MD, expresses the efficacy of infigratinib in FGFR3-altered mUC patientsПодробнее

Liquid Biopsy... - Ryan Corcoran, MGH (D3P9)Подробнее

Meet Oncologist Daniel Petrylak, MDПодробнее

Daniel P. Petrylak, MD, on the integration of liquid biopsy being targeted into the treatment of PCПодробнее

싸이토젠 대단해요.4차산업 대장주? cytogenlabs.con No.1 CTC liquid biopsy platform company.Подробнее

CTC enumeration as a prognostic biomarker in prostate cancerПодробнее

Daniel Petrylak, MD shares his thoughts on the CARD study presented at ASCO GU 2020Подробнее

Liquid Biopsy Clinical Research—Looking at Tumor Evolution with cfDNAПодробнее

How Does Liquid Biopsy Work?Подробнее

Current Status and perspectives on liquid biopsy in mCRCПодробнее

Liquid biopsy applicationsПодробнее

Daniel Petrylak, MD, explains the effect of second antigen spread in mCRPC patientsПодробнее

The role of liquid biopsy in cancer monitoringПодробнее

Webinar: Stephen Bagley, MD - Liquid Biopsy for Brain Tumors: Recent Advances and Future DirectionsПодробнее

Dr. Polsky on the Unmet Need of Clinical Utility in Liquid BiopsyПодробнее